Key result
Obesity linked to ~125% longer trazodone elimination half-life due to increased volume of distribution.
Why the study?
How do age, gender, and obesity affect the pharmacokinetics of single-dose trazodone?
Observational (n=89)
How do age, gender, and obesity affect the pharmacokinetics of single-dose trazodone?
Absolute Event Rate: 13.3% vs 5.9%
p-value: p=<0.001
Trazodone clearance is reduced in elderly men, suggesting a need for dosage reduction, while dosing in obese individuals should be based on ideal body weight due to increased volume of distribution and prolonged half-life.
No takes yet. Share an insight, caveat, or question.
May support ideal body weight-based trazodone dosing in obesity; extends pharmacokinetic data but leaves open need for prospective validation.
Greenblatt et al. (1987) conducted an observational in Healthy and obese subjects (n=89). Obesity and advanced age vs. Normal weight and young subjects was evaluated on Elimination half-life (t1/2) in obese vs normal weight subjects (p=<0.001). Obesity significantly prolonged trazodone elimination half-life compared to normal weight controls (13.3 vs. 5.9 hours; P<0.001) due to a greatly increased volume of distribution.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: